Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Mylan to pay $30 million U.S. SEC fine related to EpiPen overcharge probe

Mylan NV agreed to settle U.S. SEC charges that the company hid from investors the impact of a federal probe into the drugmaker’s overbilling the government for the EpiPen allergy treatment.

Read More »

Many epinephrine self-injectors still potent long after expiration date

EpiPens and other autoinjectors filled with epinephrine to treat severe allergic reactions may still be potent enough to work many months past their labeled expiration date, according to a study that concludes patients might need expensive refills less often.

Read More »

Pfizer unit Meridian under civil investigation by U.S. Attorney

Pfizer Inc. received a request for documents as part of a U.S. investigation related to quality issues involving the manufacture of auto-injectors at the company’s Meridian Medical Technologies site.

Read More »

Exclusive: Teva’s generic EpiPen launch stalls months after approval

Many of the largest U.S. pharmacies and drug distributors do not have Teva Pharmaceutical Industries Ltd.’s generic version of EpiPen five months after the life-saving allergy treatment was approved for sale in the United States, pharmacy chains and a group that tracks drug shortages told Reuters.

Read More »

Gilead to launch generic hepatitis drugs

Gilead Sciences Inc. plans to launch generic versions of the company’s hepatitis C drugs in the United States, at a time when regulators are looking to lower healthcare costs.

Read More »

Walgreens to supply Kaleo’s allergy shots as EpiPen shortage drags

Walgreens Boots Alliance Inc. said emergency allergy shots from Kaleo will be available in the U.S. drugstore chain’s stores, the latest effort to address shortages of the lifesaving treatment during the back-to-school season.

Read More »

FDA extends EpiPen expiry date to combat shortage

The U.S. Food and Drug Administration extended the expiration date of specific lots of Mylan NV’s EpiPen allergy injectors by four months to mitigate the shortage of the life-saving treatment.

Read More »

FDA approves Teva’s generic of Mylan’s EpiPen

The U.S. Food and Drug Administration approved Teva Pharmaceutical Industries Ltd.’s generic version of Mylan NV’s life-saving allergy injection EpiPen.

Read More »

Adamis Pharma Sells Epinephrine Injector Rights to Novartis

Adamis Pharmaceuticals is selling U.S. commercial rights to Symjepi, a competitor to Mylan’s EpiPen, to Novartis.

Read More »

FDA says Mylan’s EpiPen is in shortage

U.S. regulators said Mylan NV’s EpiPen products are in shortage, due to manufacturing delays that are creating intermittent supply constraints of the emergency allergy treatment.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!

Subscribe

Ad Right Bottom